retatrutide weight loss retatrutide clinical trial results Eli Lilly's Phase 3 Results: 28.7% | Drug Discovery & Development posted on the topic Effects of once-weekly subcutaneous retatrutide
Description
Table 1 Adapted form: Long B, Pelletier J, Koyfman A, Bridwell RE
Signs and symptoms present around 2 to 4 years of age and include hydrocephalus, seizures, behavioral changes, cognitive decline, hearing loss and speech delay
J Am Coll Cardiol (2020) 75(16):195674
You Already Make GLP-1
In the intention-to-treat analysis, the estimated treatment difference for total body fat was 3.1 1.4 kg (95% CI 5.7 to 0.4 kg, P = .02)
Psychological and emotional factors should not be underestimated
